Comparing Revenue Performance: BioMarin Pharmaceutical Inc. or Lantheus Holdings, Inc.?

BioMarin vs. Lantheus: A Decade of Revenue Growth

__timestampBioMarin Pharmaceutical Inc.Lantheus Holdings, Inc.
Wednesday, January 1, 2014751040000301600000
Thursday, January 1, 2015889895000293461000
Friday, January 1, 20161116854000301853000
Sunday, January 1, 20171313646000331378000
Monday, January 1, 20181491212000343374000
Tuesday, January 1, 20191704048000347337000
Wednesday, January 1, 20201860455000339410000
Friday, January 1, 20211846275000425208000
Saturday, January 1, 20222096039000935061000
Sunday, January 1, 202324192260001296429000
Monday, January 1, 20242853915000
Loading chart...

Data in motion

Revenue Growth: BioMarin vs. Lantheus

In the competitive landscape of the pharmaceutical industry, revenue growth is a key indicator of success. Over the past decade, BioMarin Pharmaceutical Inc. has consistently outperformed Lantheus Holdings, Inc. in terms of revenue. From 2014 to 2023, BioMarin's revenue surged by over 220%, reaching its peak in 2023. In contrast, Lantheus experienced a more modest growth of approximately 330% during the same period, with a significant leap in 2023.

A Decade of Change

BioMarin's revenue growth reflects its strategic focus on innovative therapies, while Lantheus's recent uptick suggests a promising shift in its market strategy. The data highlights a pivotal year in 2022, where Lantheus's revenue nearly tripled, indicating a potential breakthrough in its operations. As we look to the future, these trends offer valuable insights into the evolving dynamics of the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025